Buscar
Fate Therapeutics Inc
FATEAñadir a la lista de seguimiento
2.420USD
+0.010+0.41%
Cierre 07-27 16:00（ET）Cotizaciones retrasadas 15 min
281.38MCap. mercado
PérdidaP/E TTM
Más Datos de Fate Therapeutics Inc Compañía
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Información de Fate Therapeutics Inc
Símbolo de cotizaciónFATE
Nombre de la empresaFate Therapeutics Inc
Fecha de salida a bolsaOct 01, 2013
Director ejecutivoValamehr (Bahram)
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
Dirección12278 Scripps Summit Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92131
Teléfono18588751803
Sitio Webhttps://fatetherapeutics.com/
Símbolo de cotizaciónFATE
Fecha de salida a bolsaOct 01, 2013
Director ejecutivoValamehr (Bahram)
Ejecutivos de Fate Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
642.42K
+3.89%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
239.70K
+58.86%
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
64.80K
-44.67%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
36.33K
+68.81%
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Independent Director
Independent Director
--
--
Mr. Kamal Adawi
Mr. Kamal Adawi
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
642.42K
+3.89%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
239.70K
+58.86%
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
64.80K
-44.67%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
36.33K
+68.81%
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Fate Therapeutics Inc?
Los cinco principales accionistas de Fate Therapeutics Inc son: Dr. William H. (Bill) Rastetter, Ph.D.
¿Cuántas instituciones poseen acciones de Fate Therapeutics Inc (FATE)?
A fecha de 2026Q1, 379 instituciones poseen acciones de Fate Therapeutics Inc, con un valor de mercado combinado de aproximadamente 92.31M, lo que representa el 79.47% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -39055587.00.